B-type natriuretic peptide as an indicator of right ventricular dysfunction in acute pulmonary embolism. 2008

T Yardan, and L Altintop, and A Baydin, and O Yilmaz, and H Guven
Ministry of Health, Ankara Training & Research Hospital, Emergency Service, Ankara, Turkey. tyardan@yahoo.com

OBJECTIVE B-type natriuretic peptide (BNP) is a neurohormone secreted from cardiac ventricles in response to ventricular strain. The aim of present study was to evaluate the role of BNP in the diagnosis of the right ventricular (RV) dysfunction in acute pulmonary embolism (PE). METHODS BNP levels were measured in patients with acute PE as diagnosed by high probability lung scan or positive spiral computed tomography. All patients underwent standard echocardiography and blood tests during the second hour of the diagnosis. RESULTS Forty patients diagnosed as acute PE (mean age, 60.4 +/- 13.2 years; 62.5% women) were enrolled in this study. Patients with RV dysfunction had significantly higher BNP levels than patients without RV dysfunction (426 +/- 299.42 pg/ml vs. 39.09 +/- 25.22 pg/ml, p < 0.001). BNP-discriminated patients with or without RV dysfunction (area under the receiver operating characteristic curve, 0.943; 95% CI, 0.863-1.022). BNP > 90 pg/ml was associated with a risk ratio of 165 (95% CI, 13.7-1987.2) for the diagnosis of RV dysfunction. There was a significant correlation between RV end-diastolic diameter and BNP (r = 0.89, p < 0.001). Sixteen patients (40%) were diagnosed as having low-risk PE, 19 patients (47.5%) with submassive PE and five patients (12.5%) with massive PE. The mean BNP was 39.09 +/- 25.2, 378.4 +/- 288.4 and 609.2 +/- 279.2 pg/ml in each group respectively. CONCLUSIONS Measurement of BNP levels may be a useful approach in diagnosis of RV dysfunction in patients with acute PE. The possibility of RV dysfunction in patients with plasma BNP levels > 90 pg/ml should be strongly considered.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011655 Pulmonary Embolism Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS. Pulmonary Thromboembolism,Thromboembolism, Pulmonary,Embolism, Pulmonary,Embolisms, Pulmonary,Pulmonary Embolisms,Pulmonary Thromboembolisms,Thromboembolisms, Pulmonary
D004812 Epidemiologic Methods Research techniques that focus on study designs and data gathering methods in human and animal populations. Epidemiologic Method,Epidemiological Methods,Methods, Epidemiologic,Epidemiological Method,Method, Epidemiologic,Method, Epidemiological,Methods, Epidemiological
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D018497 Ventricular Dysfunction, Right A condition in which the RIGHT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE or MYOCARDIAL INFARCTION, and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the right ventricular wall. Right Ventricular Dysfunction,Dysfunction, Right Ventricular,Dysfunctions, Right Ventricular,Right Ventricular Dysfunctions,Ventricular Dysfunctions, Right

Related Publications

T Yardan, and L Altintop, and A Baydin, and O Yilmaz, and H Guven
November 2001, Thrombosis and haemostasis,
T Yardan, and L Altintop, and A Baydin, and O Yilmaz, and H Guven
December 2008, Clinica chimica acta; international journal of clinical chemistry,
T Yardan, and L Altintop, and A Baydin, and O Yilmaz, and H Guven
June 2005, Journal of cardiac failure,
T Yardan, and L Altintop, and A Baydin, and O Yilmaz, and H Guven
June 2013, Thrombosis research,
T Yardan, and L Altintop, and A Baydin, and O Yilmaz, and H Guven
January 2005, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology,
T Yardan, and L Altintop, and A Baydin, and O Yilmaz, and H Guven
March 2015, Medicina clinica,
T Yardan, and L Altintop, and A Baydin, and O Yilmaz, and H Guven
January 2014, The Indian journal of chest diseases & allied sciences,
T Yardan, and L Altintop, and A Baydin, and O Yilmaz, and H Guven
December 2021, ESC heart failure,
Copied contents to your clipboard!